CLRB Cellectar Biosciences Inc: רווח למניה ב-12 החודשים האחרונים

The targeted oncology sector delivers explosive profit growth following product certification. The rolling period's annual change in net income per share reflects the asset's dynamics, where the current status is 65.80. Exclusive PDC patents guarantee business resilience, while the high qualification of the radiopharmaceutical staff, secured by stock option programs, minimizes the risk of losing key competencies under strict FDA oversight for Cellectar Biosciences (CLRB).

For Cellectar Biosciences (CLRB), which is currently in the pre-commercial stage of radiopharmaceutical development, investment potential is driven by the anticipation of NDA approval rather than current cash flow. By analyzing the annual EPS TTM YoY trend, an investor assesses the rate of change in net income per share over twelve months, allowing for the differentiation of actual business scaling from rising operating expenses to determine the final cost of capital.